RT info:eu-repo/semantics/article
T1 HGF, IL-1α, and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients
A1 Tamayo Velasco, Álvaro
A1 Martínez de Paz, Pedro José
A1 Pañarrubia Ponce, María Jesús
A1 Fuente, Ignacio de la
A1 Pérez González, Sonia
A1 Fernández Martínez, Itziar
A1 Dueñas Gutiérrez, Carlos Jesús
A1 Gómez Sánchez, Esther
A1 Lorenzo López, Mario
A1 Gómez Pesquera, Estefanía
A1 Heredia Rodríguez, María
A1 Carnicero Frutos, Irene
A1 Muñoz Moreno, María Fe
A1 Bernardo Ordiz, David
A1 Álvarez González, Francisco Javier
A1 Tamayo Gómez, Eduardo
A1 Gonzalo Benito, Hugo
K1 COVID-19 (Enfermedad)
K1 Cytokines
K1 Citoquinas
K1 Prognosis
K1 Pronóstico
K1 Mortality
K1 Mortalidad
AB Pneumonia is the leading cause of hospital admission and mortality in coronavirus disease 2019 (COVID-19). We aimed to identify the cytokines responsible for lung damage and mortality. We prospectively recruited 108 COVID-19 patients between March and April 2020 and divided them into four groups according to the severity of respiratory symptoms. Twenty-eight healthy volunteers were used for normalization of the results. Multiple cytokines showed statistically significant differences between mild and critical patients. High HGF levels were associated with the critical group (OR = 3.51; p < 0.001; 95%CI = 1.95–6.33). Moreover, high IL-1α (OR = 1.36; p = 0.01; 95%CI = 1.07–1.73) and low IL-27 (OR = 0.58; p < 0.005; 95%CI = 0.39–0.85) greatly increased the risk of ending up in the severe group. This model was especially sensitive in order to predict critical status (AUC = 0.794; specificity = 69.74%; sensitivity = 81.25%). Furthermore, high levels of HGF and IL-1α showed significant results in the survival analysis (p = 0.033 and p = 0.011, respectively). HGF, IL-1α, and IL 27 at hospital admission were strongly associated with severe/critical COVID-19 patients and therefore are excellent predictors of bad prognosis. HGF and IL-1α were also mortality biomarkers.
PB MDPI
SN 2077-0383
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/51601
UL https://uvadoc.uva.es/handle/10324/51601
LA eng
NO Journal of Clinical Medicine, 2021, vol. 10, n. 9, 2017
NO Producción Científica
DS UVaDOC
RD 24-nov-2024